NEURO PMR study evaluates the clinical utility and patient experience of AI-powered portable MRI in an outpatient settingGUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine,…
NEURO PMR study evaluates the clinical utility and patient experience of AI-powered portable MRI in an outpatient settingGUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine,…
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank…
RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency…
Dosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency Approximately 22% of patients reached 100%…
Expanding network’s proprietary EPICC suite of tools for secure, AI-powered replicas of both HCPs and patientsNEW YORK, Aug. 01, 2025…
HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader…
Calgary, Alberta--(Newsfile Corp. - July 31, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is…
EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a…
EDEN PRAIRIE, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a…